Mineralys Therapeutics

Mineralys Therapeutics

Pharmaceuticals
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

$1.3B

Market Cap • 11/17/2026

2019

(7 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2,5

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

5,7

EPS

—

Market Cap

Market Cap

1,3B

EV

755,9M

EV/Revenue

—

EV/EBITDA

-1,9

EV/EBIT

-1,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-35,8%

Total Yield

-35,8%

Payout

0%

Retained Earnings

-794,9M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

11,8

Quick Ratio

11,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium